Greiner Bio-One North America, Inc.

CLOSEOUT LETTER Greiner Bio-One North America, Inc. MARCS-CMS 606266 — April 25, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Arnaldo C. Marchionne Recipient Title Chairman of the Management Board Greiner Bio-One North America, Inc. 4238 Capital Drive Monroe , NC 28110 United States a.c.marchionne@gbo.com Manfred.abel@gbo.com Issuing Office: Division of Medical Device and Radiological Health Operations Central United States (407) 475-4700 Dear Mr. Marchionne: The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 606266) issued on April 16, 2020. Based on our evaluation, it appears that you have addressed the violations(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Melissa Michurski, Director Compliance Brach Office of Medical Device and Radiological Health Division 2 Content current as of: 04/27/2022 Regulated Product(s) Medical Devices